Vedanta Biosciences
Focus: Vedanta Biosciences develops live biotherapeutic products and microbiome-based therapies that modulate the interaction between the human microbiome and host immune system, primarily targeting gastroenterology indications. The company is a specialized player in the emerging microbiome therapeutics space.
Profile data last refreshed 17h ago · AI intelligence enriched 3w ago
Open Jobs
1
Should You Work at Vedanta Biosciences?
AI assessmentVedanta is a high-risk, high-reward microbiome play best suited for scientists and clinicians comfortable with early-stage uncertainty in exchange for scientific novelty and potential upside.
Why Work Here
- Join a microbiome-focused biotech at an inflection point: VE303 (C. difficile) entered Phase 3 with recent $60M funding secured (Aug 2026), signaling investor confidence in lead program
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Allay Lamp
MigraineClinical Trials (1)
NCT04841083Narrow Band Green Light and Migraine
N/AHelp build intelligence for Vedanta Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.